Posted by Michael Wonder on 17 Aug 2022
Akorn announces FDA has approved generic cetrorelix acetate
16 August 2022 - Akorn announces that it received FDA approval for a generic version of cetrorelix acetate 250 mcg powder for injection.
This is the first approved AP rated bioequivalent version of Merck Serono's Cetrotide.
The FDA granted Akorn a competitive generic therapy designation for cetrorelix acetate, a designation intended to incentivise effective development, efficient review, and timely market entry of drugs for which there is inadequate generic competition.
